Shu-Hui Liu
Chief Scientific Officer Multitude Therapeutics
Shu Hui Liu is Chief Scientific Officer at Multitude Therapeutics, where she leads the discovery and development of next generation oncology therapeutics, with a strong focus on ADCs and other large molecule modalities. An experienced tumor biologist, she oversees programs spanning target identification through preclinical and clinical development. Shu Hui brings more than 25 years of industry experience, including various leadership roles at Pfizer, and deep expertise in target biology, translational research and biologics development, supporting the advancement of innovative ADC pipelines toward global clinical impact.
Seminars
Wednesday 14th October 2026
From ADC Design Concept to Clinical Outcome: Contextualizing the Clinical Profile of Anti-MUC18 ADC AMT-253 in Melanoma
2:30 pm
- Breaking down the clinical profile to date of AMT-253 with durable response and manageable toxicity in Phase I late-line advanced melanoma clinical trial
- Recapping the translational journey of AMT-253 to highlight how design concept with T-Moiety exatecan platform leads to favorable clinical profile
- Highlighting AMT-253 clinical development strategy with first-in-class potential targeting MUC18 in melanoma
